Clinical Trials Logo

Anal Intraepithelial Neoplasia clinical trials

View clinical trials related to Anal Intraepithelial Neoplasia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01923116 Completed - HIV Clinical Trials

Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia

VACCAIN-T
Start date: August 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of the study is to assess, in a phase 1/2 study, the safety and efficacy of this synthetic vaccine SLP-HPV-01® in HIV+ men with CD4 counts > 350 x 10E6/l and HPV16-induced intra-anal high-grade AIN (grade 2-3) that failed on, or recurred after previous treatment.

NCT ID: NCT01651949 Completed - Anal Cancer Clinical Trials

Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)

Start date: October 29, 2012
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the immunogenicity and tolerability of 9vHPV (9-valent HPV vaccine, V503) in 16- to 26-year old men and women. The overall goal is to bridge 9vHPV efficacy findings in young women to young men based on the demonstration of similar immunogenicity and safety profiles. The primary hypothesis is that 9vHPV induces antibody responses at 4 weeks postdose 3 in heterosexual males that are non-inferior to antibody responses in young women.

NCT ID: NCT01637298 Completed - Clinical trials for Anal Intraepithelial Neoplasia

Biomarkers to Detect Anal Intraepithelial Neoplasia in Thai Men Who Have Sex With Men

Start date: December 2009
Phase: N/A
Study type: Observational

The goals of this application are to assess the usefulness of biomarkers, including p16 proteins, minichromosome maintenance (MCM) proteins, high-risk human papillomavirus (HPV) types, and E6 and E7 mRNA/oncoproteins, as adjunct tools to anal Pap smear in identifying HGAIN and to study the impact of HIV infection on the characteristics of anal cytology (by anal Pap smear) and biomarkers. To fulfill these goals, in addition to routine practice, it will be necessary to follow 450 MSM (315 HIV-positives and 135 HIV-negatives) over 60 months, and perform HRA and biomarkers on all clients at baseline and every 12 months. Information from this study would inform AIN screening and follow up approaches in HIV-positive and HIV-negative MSM in both resource-limited and resource-rich settings.